A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer’s disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.
In the presence of alcohol, a defective version of the aldehyde dehydrogenase 2 gene in human cell cultures and mice leads to biochemical changes associated with Alzheimer’s disease.
Home for the holidays – but will grandpa remember me? Now there’s hope; Hebrew University team finds tb vaccine lowers rates of Alzheimer’s disease in cancer patients.
Neuroscientists at Georgetown University Medical Center say they have developed and tested an agent that reduces the buildup of toxic proteins in animal models of both Parkinson’s and Alzheimer’s diseases, and improves cognitive and motor behavior.
A team of scientists from the Moscow Institute of Physics and Technology (MIPT) and Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (IBCh RAS) studied one hereditary genetic mutation to discover general molecular mechanisms that may lead both to early onset of Alzheimer’s disease and to the form of the disease caused by age-related changes in human body.